Early response rates and Curie scores at end of induction: An update from a phase II study of an anti-GD2 monoclonal antibody (mAb) with chemotherapy (CT) in newly diagnosed patients (pts) with high-risk (HR) neuroblastoma (NB).

Wayne L. Furman,Barry L. Shulkin,Sara M. Federico,Mary Beth McCarville,Andrew M. Davidoff,Matthew J. Krasin,Jianrong Wu,Rachel Brennan,Michael W. Bishop,Sara Helmig,Fariba Navid,Victor M. Santana,Gwendolyn Anthony,Jacquelyn A. Hank,Stephen D. Gillies,Paul M. Sondel,Wing Leung,Alberto S. Pappo

Early response rates and Curie scores at end of induction: An update from a phase II study of an anti-GD2 monoclonal antibody (mAb) with chemotherapy (CT) in newly diagnosed patients (pts) with high-risk (HR) neuroblastoma (NB).

2017

Wayne L. Furman
Barry L. Shulkin
Sara M. Federico
Mary Beth McCarville
Andrew M. Davidoff
Matthew J. Krasin
Jianrong Wu
Rachel Brennan
Michael W. Bishop
Sara Helmig
Fariba Navid
Victor M. Santana
Gwendolyn Anthony
Jacquelyn A. Hank
Stephen D. Gillies
Paul M. Sondel
Wing Leung
Alberto S. Pappo

10534Background: We are conducting a Phase II trial of the anti-GD2 mAb hu14.18K322A given concomitantly with CT in newly diagnosed pts with HR NB. Our primary objective is to compare the response ...

Keywords:

Neuroblastoma
Curie
Pathology
Monoclonal antibody
Cancer research
Chemotherapy
Medicine
newly diagnosed
Phases of clinical research
Oncology
Internal medicine
end of induction

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations